Ozempic, also known as semaglutide, was approved by the FDA as a weekly diabetes treatment in 2017
Although contrary to the notion that G6PD-d largely limits proliferative capacity, Varghese et al
Through expert opinions and patient experiences, we consider the need for responsible prescribing, improved education and equitable access for those who could benefit from Ozempic, Wegovy and other GLP-1 therapies
Whilst these trials primarily enrolled participants without diabetes, the findings are relevant for understanding semaglutide's weight-loss potential when used at higher doses
February 20, 2026 By: Meera Datta Colostrum: Phony or phenomenal
Real-World Effectiveness: How Much Weight Can Patients Really Lose